Inflexion Private Equity is pleased to announce it has completed a minority investment in European LifeCare Group (“ELCG”), Europe’s largest provider of vaccinations. The investment is being made by Inflexion Enterprise Fund IV, Inflexion’s dedicated lower mid-market fund.
Founded in 1998, today ELCG has over 50 specialist clinics in Denmark and the UK where the company trades under a number of brands, including London Travel Clinic. ELCG also works for both the Danish and English NHS as a contracted service provider of immunization programmes in schools and national influenza vaccination programmes. In 2018, ELCG is forecast to vaccinate approximately 400,000 individuals on behalf of the NHS in Denmark and the UK.
The travel vaccination markets in Denmark and the UK and are estimated to be worth c.£270 million and are growing at around 7% per annum as global travel increases. ELCG’s management team are looking to capitalise on this growing market by pursuing a rapid buy-and-build to double their number of clinics over the coming years drawing upon Inflexion’s minority investment and buy-and-build experience.
ELCG is led by CEO and Co-Founder Karsten Østergaard and CFO Kristian Tuft, supported by a strong management team who have been working together for over 10 years. The Inflexion deal team comprised of Tim Smallbone, Ben Long, Richard Wootten and Robin Senivassen. Bill Colvin has been appointed as the Non-Executive Chairman.
ELCG is a leading company in a rapidly growing niche market. The team have strong experience in building their business both through acquisitions and opening new clinics. They are the number one consolidator in a fragmented market which also has scope to benefit from additional clinic openings. We look forward to working with them to accelerate ELCG’s already impressive growth.
Contact us
Please contact us if you have any media enquiries
